Interferon Gamma-Induced Protein (IP-10) as Potential Biomarker for Cancer-Related-Fatigue: Results from a 6-month Randomized Controlled Trial

Emil ter Veer, Hetty Prinsen, Mirjam A. G. Sprangers, Koos A. H. Zwinderman, Gijs Bleijenberg, Tineke C. T. M. van der Pouw Kraan, I. Jolanda M. de Vries, Eddy A. Wierenga, Hanneke W. M. van Laarhoven

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We examined if serum concentrations Interferon gamma-induced protein (IP-10) is a potential clinical biomarker for cancer-related-fatigue (CRF). Fatigue scores and IP-10 concentrations were measured from curatively treated fatigued cancer patients randomized to either cognitive behavioral therapy (CBT, n = 26) or waiting-list (WL, n = 13). No correlation was found between baseline IP-10 level and fatigue severity and no significant differences in IP-10 serum levels were observed between fatigued and matched non-fatigued patients (n = 22). Relative changes in IP-10 concentrations from baseline to six-month follow-up were not significantly different between the CBT and WL conditions. In this study, IP-10 showed low potential as clinical CRF biomarker. Trial registration: This study is registered at ClinicalTrials.gov (NCT01096641).
Original languageEnglish
Pages (from-to)371-377
JournalCancer Investigation
Volume36
Issue number7
DOIs
Publication statusPublished - 2018

Cite this